Respiratorius AB (publ) is a Sweden-based biotechnology and pharmaceutical company. It develops candidate drugs for treatment of cancer, Chronic Obstructive Pulmonary Disease (COPD) and asthma. The project portfolio also includes development of a biomarker for cardiovascular positron-emission tomography (PET)-imaging. The oncology drug project VAL-001 aims for first-line treatment of Diffuse Large B-Cell Lymphoma (DLBCL). In the COPD and asthma projects, the Company develops two classes of drug substances, such as RESP-1000 and RESP-2000 series for bronchodilating effect on small airways. The Company’s primary markets are the United States and South Africa.